Literatur
-
1
Anker S D, Comin Colet J, Filippatos G. et al .
Ferric carboxymaltose in
patients with heart failure and iron deficiency.
N Engl
J Med.
2009;
361
2436-2448
-
2
Bardy G H, Lee K L, Mark D B. et al .
Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure.
N
Engl J Med.
2005;
352
225-237
-
3
Bhatia R S, Tu J V, Lee D S. et al .
Outcome of heart failure with preserved
ejection fraction in a population-based study.
N Engl
J Med.
2006;
355
260-269
-
4
Böhm M, Swedberg K, Komajda M. et al .
Heart rate as a risk factor in chronic
heart failure (SHIFT): the association between heart rate and outcomes
in a randomised placebo-controlled trial.
Lancet.
2010;
376
886-894
-
5
Cleland J G, Daubert J C, Erdmann E. et al .
The effect of cardiac resynchronization
on morbidity and mortality in heart failure.
N Engl J
Med.
2005;
352
1539-1549
-
6
Dickstein K, Cohen-Solal A, Filippatos G. et al .
ESC Guidelines for the diagnosis and treatment
of acute and chronic heart failure 2008: the Task Force for the
Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
of the European Society of Cardiology. Developed in collaboration with
the Heart Failure Association of the ESC (HFA) and endorsed by the
European Society of Intensive Care Medicine (ESICM).
Eur
Heart J.
2008;
29
939-989
-
7
Dickstein K, Vardas P E, Auricchio A. et al .
2010 Focused Update of ESC Guidelines on device
therapy in heart failure.
Eur Heart J.
2010;
31
2677-2687
-
8
Granger C B, McMurray J J, Yusuf S. et al .
Effects of candesartan in patients with
chronic heart failure and reduced left-ventricular systolic function
intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative
trial.
Lancet.
2003;
362
772-776
-
9
Lainscak M, Anker S D.
Prognostic factors
in chronic heart failure. A review of serum biomarkers, metabolic
changes, symptoms, and scoring systems.
Herz.
2009;
34
141-147
-
10
Moss A J, Zareba W, Hall W J. et al .
Prophylactic implantation of a defibrillator
in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med.
2002;
346
877-883
-
11
Neumann T, Biermann J, Erbel R. et al .
Heart failure: the commonest reason for
hospital admission in Germany: medical and economic perspectives.
Dtsch Arztebl Int.
2009;
106
269-275
-
12
Pfeffer M A, McMurray J J, Velazquez E J. et al .
Valsartan, Captopril,
or both in myocardial infarction complicated by heart failure, left ventricular
dysfunction, or both.
N Engl J Med.
2003;
349
1893-1906
-
13
Pitt B, Remme W, Zannad F. et
al .
Eplerenone, a selective aldosterone blocker, in
patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med.
2003;
348
1309-1321
-
14
Pitt B, Zannad F, Remme W J. et al .
The effect of spironolactone on morbidity
and mortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Investigators.
N Eng J Med.
1999;
341
709-717
-
15
Sipahi I, Debanne S M, Rowland D Y. et al .
Angiotensin-receptor blockade
and risk of cancer: meta-analysis of randomised controlled trials.
Lancet Oncol.
2010;
11
627-636
-
16
Störk S, Faller H, Schowalter M. et al .
Evidenz-basiertes Krankheitsmanagement bei
Herzinsuffizienz (HeartNetCare-HF Würzburg).
Dtsch
Med Wochenschr.
2009;
134
773-776
-
17
Störk S, Hense H W, Zentgraf C. et al .
Pharmacotherapy according to treatment
guidelines is associated with lower mortality in a community-based
sample of patients with chronic heart failure: a prospective cohort
study.
Eur J Heart Fail.
2008;
10
1236-1245
-
18
Swedberg K, Komajda M, Böhm M. et al .
Ivabradine and outcomes in chronic heart
failure (SHIFT): a randomised placebo-controlled study.
Lancet.
2010;
376
875-885
-
19
Tang A S, Wells G A, Talajic M. et al .
Cardiac-resynchronization therapy for mild-to-moderate
heart failure.
N Engl J Med.
2010;
363
2385-2395
-
20
The SOLVD Investigators .
Effect of enalapril on survival in patients with reduced left ventricular
ejection fractions and congestive heart failure.
New Engl
J Med.
1991;
325
293-302
-
21
Zannad F, McMurray J J, Krum H. et al .
Eplerenone in patients with systolic heart
failure and mild symptoms.
N Engl J Med.
2011;
364
11-21
Prof. Dr. med. Marc W. Merx
Universitätsklinikum Düsseldorf
Klinik
für Kardiologie, Pneumologie, Angiologie
Moorenstr.
5
40225 Düsseldorf
Phone: 0211/8116674
Fax: 0211/8118812
Email: Marc.Merx@med.uni-duesseldorf.de
